Kriya Therapeutics IPO
Kriya Therapeutics is a gene therapy company developing treatments for chronic diseases including diabetes, obesity, and ophthalmology conditions. The company uses adeno-associated virus (AAV) vectors to deliver therapeutic genes and focuses on diseases with significant unmet medical needs. Investors are interested in its IPO potential due to its promising pipeline and the high-growth gene therapy market.
Key Facts
| Industry | Gene Therapy |
| Founded | 2019 |
| Headquarters | Palo Alto, CA |
| Employees | ~150 |
| Website | kriyatherapeutics.com |
| Funding | Series B raised $165M in 2021. Total raised: ~$229M |
About Kriya Therapeutics
Kriya Therapeutics is a gene therapy company focused on developing treatments for highly prevalent diseases, particularly metabolic disorders like diabetes and obesity. The company utilizes adeno-associated virus (AAV) vectors to deliver therapeutic genes directly to target tissues, aiming to provide long-lasting treatment effects with single administrations. Their lead programs target Type 1 diabetes, diabetic retinopathy, and primary hyperoxaluria.
Founded by industry veterans with experience from companies like Gilead and Genentech, Kriya differentiates itself by focusing on common diseases rather than rare conditions, potentially addressing much larger patient populations. The company's approach involves engineering novel AAV vectors and optimizing gene circuits to achieve sustained therapeutic protein expression, representing a significant advancement in making gene therapy accessible for widespread metabolic conditions.
IPO Status
Kriya Therapeutics has not announced IPO plans and remains a private biotechnology company focused on advancing its gene therapy pipeline through clinical trials. The company raised $112 million in Series B funding in 2022 to support its clinical development programs. Kriya has multiple programs in development, including treatments for diabetic retinopathy and other chronic conditions. As a clinical-stage biotech company, Kriya would typically need to show significant clinical progress and potentially approach commercialization before considering an IPO. The gene therapy sector has seen both successes and challenges in public markets, with investor interest varying based on clinical data and regulatory progress. There are no confirmed details about the company's IPO timeline, and it likely remains focused on executing its clinical development strategy.
Competitors
Frequently Asked Questions
Does Kriya Therapeutics have a stock?
No, Kriya Therapeutics has not had an IPO and remains a private gene therapy company. The company has not announced any plans to go public.
When is the Kriya Therapeutics IPO date?
There is no announced IPO date for Kriya Therapeutics. The company has not filed for an IPO or indicated when it might consider going public.
How can I buy Kriya Therapeutics stock?
You cannot buy Kriya Therapeutics stock as it is a private company that has not gone public. The company's shares are not available on public stock exchanges.
Stay Updated on the Kriya Therapeutics IPO
Get real-time alerts when Kriya Therapeutics files for an IPO, prices shares, or begins trading.
Get IPO Alerts